
Ksilink’s pipeline of drug discovery programs
Ksilink’s coherent pipeline of drug discovery programs aims to deliver patient-based screenable disease models and first-in-class preclinical candidates to the pharmaceutical industry in the field of muscular disorders, diseases of the central nervous system (CNS), and oncology.
Ksilink is seeking to either spin-out or partner these programs in return for upfront payments, milestones and royalties.
Truly patient-based!

Myotonic Dystrophy Type 1 (MD1)
Project partnered
Dilated Cardio Myopathy (DCM)
Project open for codevelopment
Schizophrenia
Project open for codevelopment
Smarca2 in Cancer
Project open for codevelopment
Parkinson’s Disease
Project open for codevelopment
Autism Spectrum Disorders (ASD)
Project open for codevelopment
Myofibrillar Myopathy
Project open for codevelopment